Pharmacological activation of FOXO3 suppresses triple-negative breast cancer  in vitro  and  in vivo

See-Hyoung Park; Young Min Chung; Jessica Ma; Qin Yang; Jonathan S. Berek; Mickey C-T. Hu

doi:10.18632/oncotarget.9881

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo

See-Hyoung Park, Young Min Chung, Jessica Ma, Qin Yang, Jonathan S. Berek and Mickey C-T. Hu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:42110-42125. https://doi.org/10.18632/oncotarget.9881

Metrics: PDF 2213 views | HTML 3126 views | ?

Abstract

See-Hyoung Park1,2,*, Young Min Chung1,*, Jessica Ma1, Qin Yang3, Jonathan S. Berek1, Mickey C-T. Hu1

1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA

2Current address: Department of Biological and Chemical Engineering, Hongik University, Sejong, 339-701, Korea

3Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO 63108, USA

*These authors contributed equally to this work

Correspondence to:

Mickey C-T. Hu, email: [email protected]

Keywords: FOXO3, breast cancer, bepridil, trifluoperazine, dopamine receptor

Received: January 18, 2016 Accepted: May 12, 2016 Published: June 07, 2016

ABSTRACT

Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer. Lacking effective therapeutic options hinders treatment of TNBC. Here, we show that bepridil (BPD) and trifluoperazine (TFP), which are FDA-approved drugs for treatment of schizophrenia and angina respectively, inhibit Akt-pS473 phosphorylation and promote FOXO3 nuclear localization and activation in TNBC cells. BPD and TFP inhibit survival and proliferation in TNBC cells and suppress the growth of TNBC tumors, whereas silencing FOXO3 reduces the BPD- and TFP-mediated suppression of survival in TNBC cells. While BPD and TFP decrease the expression of oncogenic c-Myc, KLF5, and dopamine receptor DRD2 in TNBC cells, silencing FOXO3 diminishes BPD- and TFP-mediated repression of the expression of these proteins in TNBC cells. Since c-Myc, KLF5, and DRD2 have been suggested to increase cancer stem cell-like populations in various tumors, reducing these proteins in response to BPD and TFP suggests a novel FOXO3-dependent mechanism underlying BPD- and TFP-induced apoptosis in TNBC cells.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9881

Publication Alerts

Research Papers:

Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo

Abstract